Previous 10 | Next 10 |
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , Jan. 2, 2024 ...
2023-12-27 16:26:14 ET More on Regulus Therapeutics Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics For further details see: Regulus Therapeutics ...
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of i...
2023-11-10 11:06:49 ET More on Regulus Therapeutics Regulus posts early Phase 1 data for lead asset in kidney disease Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regul...
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant P...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Regulus Therapeutics Inc. (RGLS) is expected to report $-0.36 for Q3 2023
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- ...
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Regulus Therapeutics I...
2023-09-20 08:53:10 ET More on Regulus Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics For further details see: Regulus posts early Phase 1 data f...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Domin...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial re...